

Commitment to Early Infant HIV Diagnosis


*Expansion of HIV Qualitative testing to
cobas[®] 4800 and cobas[®] 6800/8800 Systems*



The impact of early infant diagnosis

The number of children younger than 15 receiving life-saving antiretroviral therapy (ART) globally increased from 435,000 in 2010 to 948,000 in 2019.¹

From 2010 to 2016 the number of children aged 0–14 years dying of AIDS-related illnesses was nearly cut in half in just six years⁴



85% of pregnant women living with HIV had access to antiretroviral medicines to prevent transmission of HIV to their child in 2019²

Since the inception of the initial Public Private Partnership focused on EID in 2009, annual infant screening has scaled up by >200%*

** Internal data*

Expansion of Prevent-Mother-to-Child-Transmission (PMTCT) programs have helped avoid approximately 1.4 million new HIV infections among children between 2010 and 2018.³


Streamlined DBS workflow

	<p>1. Obtain sample & preparation of dried blood spots</p> <p>Collect dried blood spot (DBS) samples using appropriate clinical procedures. DBS are prepared by collecting 70 µL of human whole blood onto a delineated circle on a filter card or specimen collection card, and allowing it to dry at ambient temperature for at least 3 hours.</p>
	<p>2. Extraction from paper filter & resuspension</p> <p>For early infant diagnosis testing, remove one full single dried blood spot from the filter card and resuspend the DBS by simply adding the appropriate resuspension reagent listed in the method sheet.</p>
	<p>3. Automated specimen preparation</p> <p>The samples are then ready for automated specimen preparation on the Roche platform.</p>
	<p>4. Automated amplification and detection</p> <p>Amplification occurs on the Roche platform. The innovative Dual Target HIV-1 assay design measures two unique regions of the HIV-1 genome, which are not subject to selective drug pressure.</p>


Consistent performance across all platforms




cobas® 6800/8800 Systems



cobas® 4800 System (HIV-1 used for Qualitative Detection)



COBAS® AmpliPrep/COBAS® TaqMan®



References

- 1 https://data.unicef.org/wp-content/uploads/2019/07/HIV_Paediatric_ART_Coverage_2020.xlsx
- 2 <https://www.unaids.org/en/resources/fact-sheet>
- 3 <https://www.avert.org/professionals/hiv-programming/prevention/prevention-mother-child>
- 4 https://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf (pg. 23)

COBAS, AMPLIPREP and TAQMAN are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.

© 2020 Roche

Published by:

Roche Molecular Systems
4300 Hacienda Drive
Pleasanton, CA 94588 USA

<http://diagnostics.roche.com>